Previous close | 3.3400 |
Open | 3.3400 |
Bid | 3.3500 x 1800 |
Ask | 3.3600 x 900 |
Day's range | 3.2613 - 3.4550 |
52-week range | 3.2200 - 25.0550 |
Volume | |
Avg. volume | 758,065 |
Market cap | 317.273M |
Beta (5Y monthly) | 3.41 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.9440 |
Earnings date | 01 Aug 2022 - 05 Aug 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 16.50 |
CAMBRIDGE, Mass., May 10, 2022--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will present data from its ECOSPOR III trial of SER-109 at the Digestive Disease Week® (DDW) Annual Meeting, which is taking place May 21-24, 2022. SER-109 is an investigational oral microbiome therapeutic for the prevention of recurrent C. difficile infection (rCDI). With an oral and poster presentation, Seres will present data on how SER-109 restores the f
Market forces rained on the parade of Seres Therapeutics, Inc. ( NASDAQ:MCRB ) shareholders today, when the analysts...
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -8.93% and 79.01%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?